BioPharma Credit PLC TRIGGER OF A CONTINUATION RESOLUTION (9416R)
01 November 2023 - 6:00PM
UK Regulatory
TIDMBPCR
RNS Number : 9416R
BioPharma Credit PLC
01 November 2023
1 November 2023
BIOPHARMA CREDIT PLC
(THE "COMPANY")
Trigger of a continuation resolution
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences
debt investor, announces that in accordance with Article 152(2) of
the articles of association of the Company (the "Articles"), a
Continuation Resolution has been triggered on account of the
Company's shares having traded, on average, at a discount in excess
of 10% to the Net Asset Value per Share over the 12-month rolling
period ending on 31 October 2023. Pursuant to the Articles, a
general meeting must be convened proposing a Continuation
Resolution no later than 31 December 2023. The Company will
announce further details in due course regarding the timing and
agenda of the General Meeting. The Board will recommend that
shareholders vote in favour of continuation.
The Company is also required to offer a further Continuation
Resolution to the shareholders pursuant to Article 152(1) of the
Articles at its annual general meeting in 2025.
Enquiries:
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBIBDGLSXDGXB
(END) Dow Jones Newswires
November 01, 2023 03:00 ET (07:00 GMT)
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
From Dec 2023 to Dec 2024